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Abstract
Background: The aim of this study was to evaluate the clinical efficacy of postoperative adjuvant transcatheter
arterial chemoembolization (TACE) on hepatocellular carcinoma (HCC).
Methods: Data from 117 patients with HCC who underwent hepatectomy between December 2010 and February
2014 were retrospectively reviewed. In total, 55 patients underwent surgical resection only (group A), and 62 patients
underwent surgical resection with adjuvant TACE (group B). The perioperative clinical indicators, postoperative
sequential treatment, and follow-up were compared between the two groups of patients. The Kaplan-Meier method
was used to compare survival between the groups, and prognostic factors were evaluated by a Cox proportional
hazard model.
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Results: The two groups showed no significant difference in age, gender, preoperative A-fetoprotein (AFP) values,
preoperative Child-Pugh score, hepatitis B virus(HBV) DNA levels, duration of surgery, hepatectomy technique, albumin
values 1-week postoperative, postoperative complications, duration of postoperative hospital stay, cirrhosis, tumor size,
tumor differentiation, tumor encapsulation, satellite nodules, or microvascular infiltration. Cox regression analysis revealed
that tumor size, satellite nodules, and microvascular infiltration were significantly independent prognostic factors (P =
0.001, 0.002, and 0.001). Of the 117 patients, the 1-, 2-, and 3-year disease-free survival rates were 64.5, 50.0, and 41.9 %,
respectively, for group B (62 patients) and 45.5, 36.4, and 30.9 %, respectively, for group A (55 patients). Although
improving trends of disease-free survival were observed in the adjuvant TACE group, there was a significant difference in
postoperative 1-year survival between the two groups (P = 0.04) but no significant difference in postoperative 2- and 3-
year survival. In patients with tumor size >5 cm, the 1-, 2-, and 3-year disease-free survival rates were 41.7, 25.0, and
12.5 %, respectively, for group B and 11.8, 0, and 0 %, respectively, for group A. There was a significant difference in
postoperative 1- and 2-year survival between the two groups (P = 0.04 and 0.03, respectively) but no significant difference
in postoperative 3-year survival. In patients with microvascular infiltration, the 1-, 2-, and 3-year disease-free survival rates
were 42.3, 26.9, and 15.4 %, respectively, for group B and 12.5, 4.2, and 0 %, respectively, for group A. There was a
significant difference between the two groups (P = 0.02, 0.03, and 0.045, respectively). In patients with satellite nodules,
the 1-, 2-, and 3-year disease-free survival rates were 50.0, 50, and 40 %, respectively, for group B and 17.6, 0, and 0 %,
respectively, for group A. There was a significant difference between the two groups (P = 0.04, 0.01, and 0.03, respectively).
In patients with tumor size ≤5 cm, without satellite nodules, or without microvascular infiltration, there was no significant
difference between the two groups in the 1-, 2-, or 3-year disease-free survival rates. Of 117 patients overall, 18 (15.4 %)
developed hepatitis B virus reactivation: 2 (3.6 %) patients in group A and 16 (25.8 %) patients in group B. There was a
significant difference between the two groups (P = 0.000). Of these patients, one (1.8 %) patient in group A and five
(8.1 %) patients in group B developed hepatitis due to hepatitis B virus reactivation. There was a significant difference
between the two groups (P = 0.000).
Conclusions: Postoperative adjuvant TACE can improve the 1-year disease-free survival rate of HCC patients.
Postoperative adjuvant TACE may improve 2- and 3-year disease-free survival rates, but no statistical significance was
found. For patients with tumor size >5 cm, postoperative adjuvant TACE can improve 1- and 2-year disease-free
survival rates, and postoperative adjuvant TACE may improve the 3-year disease-free survival rate. For HCC patients
with tumor size ≤5 cm, postoperative adjuvant TACE may improve the 1-, 2-, and 3-year disease-free survival rates, but
no statistical significance was found. For patients with microvascular infiltration or satellite nodules, postoperative
adjuvant TACE can improve the 1-, 2-, and 3-year disease-free survival rates. For patients without microvascular
infiltration or without satellite nodules, postoperative adjuvant TACE cannot improve 1-, 2-, or 3-year disease-free
survival rates. For patients with tumor size >5 cm with microvascular infiltration or with satellite nodules, postoperative
adjuvant TACE was suggested. Hepatitis B virus reactivation can occur in patients with postoperative adjuvant TACE;
thus, antiviral treatment was suggested for these patients.
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Background
Hepatocellular carcinoma (HCC), which is the sixth most
common cancer and the third most common cause of
cancer death, is the most common primary malignancy of
the liver [1]. In China, nearly 90 % of HCC patients with
chronic hepatitis B develop HCC through the “chronic
hepatitis B-hepatitis, cirrhosis-primary hepatocellular car-
cinoma” trilogy. Radical hepatectomy is the most effective
treatment for HCC, but there is a higher recurrence rate.
The postoperative 5-year recurrence rate is 70–80 %, and
the postoperative 5-year survival rate is 30–50 %.
In 1976, Goldstein first reported using transcatheter ar-
terial chemoembolization (TACE) to treat HCC, and since
then, TACE has been recognized as the preferred non-
surgical method to treat HCC. Adjuvant TACE, as one of
the measures to prevent the recurrence of HCC after sur-
gery, is now widely used clinically and has accumulated
substantial data, but its effects are still controversial and
difficult to determine. This study analyzed the clinical data
of 117 HCC patients with chronic hepatitis B who were
treated from December 2010 to February 2014 in our hos-




This study included 117 patients with HCC who under-
went radical hepatectomy. The entry criteria included the
following: (1) all of the tumor lesions were removed,
which was judged by the surgeon’s gross inspection; (2) no
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lymph node involvement; and (3) no distant metastasis. All
of the patients were diagnosed with HCC according to the
histological findings, and we excluded the cutting-edge
cases of cancer tissue residue. Group A was composed of
55 patients who underwent simple radical resection: 45
males and 10 females, aged 31–73 years, with a mean age
of 53.8 ± 10.5 years. Group B included 62 cases of radical
resection combined with sequential TACE: 49 males
and 13 females, aged 29–81 years, with a mean age
of 56.4 ± 11.7 years. For the use of these clinical materials
for research purposes, prior consents from the patients
and approval from the Ethics Committees of The Second
Affiliated Hospital of Dalian Medical University were
obtained, and all the procedures have been performed in
compliance with the Helsinki Declaration.
Preoperative evaluation
In addition to routine examination, the A-fetoprotein
(AFP) value, hepatitis B virus DNA value, Child-Pugh
score, abdominal B ultrasound, and CT were determined.
Adjuvant TACE
For group B patients, hepatic arteriography plus infusion
chemotherapy and/or TACE was carried out convention-
ally at postoperative 1, 3, 6, and 12 months. Using the Sel-
dinger method, the catheter was inserted into one side of
the hepatic artery or the tumor-feeding artery. If no recur-
rent tumors were present, only hepatic artery infusion
chemotherapy was performed: 40–60 mg/m2 epirubicin,
100 mg/m2 oxaliplatin, and 1000 mg fluorouracil. For
recurrent tumors, the microcatheter or nanocatheter was
inserted into the recurrent tumor blood vessels, followed
by chemotherapy reperfusion combined with iodized oil
emulsifier (20 mg epirubicin emulsified with 3–30 ml
30 % iodized oil suspension) embolization for each recur-
rent tumor. When the small branch of the portal vein
appeared, the lipiodol injection was stopped.
Definition
HBV reactivation was defined as a 10-fold or more increase
in HBV DNA levels compared with baseline or the appear-
ance of HBV DNA from an undetectable level at baseline
and post-TACE HBV DNA of more than 200 IU/mL. HBV
downregulation was defined as a 10-fold or more decrease
in HBV DNA levels compared with baseline or the dis-
appearance of HBV DNA from a detectable level at baseline
and a baseline HBV DNA before TACE of 200 IU/mL. Pa-
tients that did not fall into either of these categories were
defined as having a “stable status”. Hepatitis was defined as
a threefold or more increase in serum ALT levels above the
upper limit of normal (normal <40 IU/L) or an absolute in-
crease in ALT to more than 100 IU/L. Icteric hepatitis was
defined by a serum T-bil level that exceeded twice the refer-
ence range (normal <20.5 mmol/L) in the presence of hepa-
titis. Exacerbation of liver damage included both hepatitis
and icteric hepatitis, as defined above.
Follow-up
Ultrasonography was performed and AFP and hepa-
titis B virus DNA values were estimated every 2 to
A
B
Fig. 1 Tumor-free survival of the adjuvant TACE group and the control group
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Fig. 2 Tumor-free survival rates of patients with tumor diameter >5 cm
Fig. 3 Tumor-free survival rates of patients with microvascular infiltration
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3 months during the first year after hepatectomy and
every 3–6 months thereafter. If tumor recurrence was
suspected, visceral ultrasonography, computed tomog-
raphy (CT), or magnetic resonance imaging (MRI) was
performed. The follow-up time was 3 years or the day
of surgery to the time of death, and survival time was
calculated on a monthly basis.
Statistical analysis
SPSS 17.0 statistical software was used for analysis. The
significance of differences in clinical and pathological
characteristics between groups was examined with the
Chi-square test and Student’s t test. Cumulative survival
rates were obtained by the Kaplan-Meier method. Cumu-
lative survival comparison between groups was performed
with a log-rank test. Multivariate analysis for independent
prognostic factors was performed by a Cox proportional
hazards model. P values <0.05 were considered to be
statistically significant.
Results
Clinical and pathological characteristics of adjuvant TACE
and control groups
The clinical and pathological characteristics of patients in
the adjuvant TACE and control groups are summarized in
Table 1. There were no significant differences in the age,
Child-Pugh class, or AFP level between the two groups.
Postoperative complications included the following:
pleural effusion (group A: four cases, group B: seven
cases); perihepatic effusion (group A: two cases, group B:
five cases); liver abscess (group A: two cases, group B:
three cases), cholangitis (group A: two cases, group B: one
cases); and wound infection or liquid (group A: two cases,
group B: five cases).
HCC recurrence risk factors
A total of 16 clinical indicators that can affect postopera-
tive recurrence, including age, gender, tumor size, hepatitis
B virus DNA, preoperative AFP value, Child-Pugh score,
operation time, 1-week-after albumin levels, complica-
tions, average length of stay, liver resection, liver cirrhosis,
tumor capsule, vascular invasion, satellite nodules, and
tumor differentiation, were analyzed. Univariate analysis
showed that age, Child-Pugh score, preoperative AFP
values, hepatitis B virus DNA levels, tumor size, micro-
vascular infiltration, and satellite nodules were signifi-
cantly related to recurrence (P < 0.05) (Table 2). These
seven factors were introduced into a Cox regression
model for HCC cure, which showed that tumor size,
microvascular infiltration, and satellite nodules were inde-
pendent risk factors for postoperative tumor recurrence
(P = 0.001, 0.002, and 0.001, respectively) (Table 3).
Tumor-free survival of adjuvant TACE group and
control group
The 1-, 2-, and 3-year overall tumor-free survival rates of
groups A and B were 45.5, 36.4, and 30.9 % and 64.5, 50.0,
and 41.9 %, respectively. The tumor-free survival rate
Fig. 4 Tumor-free survival rate satellite nodules
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difference was statistically significant 1 year after surgery
(P = 0.04). The difference in the tumor-free survival rate at
postoperative 2 and 3 years was not statistically significant
(P > 0.05)(Fig 1). In groups A and B, the 1-, 2-, and 3-year
tumor-free survival rates of patients with tumor diameter
>5 cm were 11.8, 0, and 0 % and 41.7, 25.0, and 12.5 %,
respectively. In patients with tumor diameter >5 cm,
the postoperative 1- and 2-year tumor-free survival
rates were significantly different between groups A
and B (P = 0.04 and 0.03, respectively), but the tumor-free
survival rate at 3 years was not significantly different (P >
0.05)(Fig 2). For patients in groups A and B who had
microvascular infiltration, the 1-, 2-, and 3-year tumor-free
survival rates were 12.5, 4.2, and 0 % and 42.3, 26.9, and
15.4 %, respectively, and the difference was statistically sig-
nificant (P = 0.02, 0.03, and 0.045, respectively)(Fig 3) . In
group A and group B, patients who had satellite nodules,
the 1-, 2-, and 3-year tumor-free survival rates were 17.6, 0,
and 0 % and 50.0, 50.0, and 40.0 %, respectively, and the dif-
ference was statistically significant (P = 0.04, 0.01, and 0.03,
respectively) (Fig 4). In patients who had a tumor diameter
≤5 cm, no microvascular invasion, and no satellite nodules,
the 1-, 2-, and 3-year tumor-free survival rates after surgery
were not significantly different between groups A and B
(P > 0.05) (Table 4,5).
Hepatitis B virus reactivation after sequential TACE
Overall, in the two groups, 18 (15.4 %) patients showed
hepatitis B virus reactivation: 2 cases in group A (3.6 %)
and 16 cases in group B (25.8 %). The difference was sta-
tistically significant (P = 0.000). There were six (5.1 %) pa-
tients with hepatitis caused by hepatitis B virus
reactivation: one case in group A (1.8 %) and five cases in
group B (8.1 %), and this difference was statistically signifi-
cant (P = 0.000). There were no cases of fulminant hepatic
failure due to hepatitis B virus reactivation in either group.
Discussion
The HCC recurrence rate is 70–80 % 5 years after radical
hepatectomy; in approximately 78–96 % of these patients,
HCC recurrence occurred around the intrahepatic pri-
mary tumor location or in multiple intrahepatic locations
[2, 3]. The largest report of resected patients comes from
the Liver Cancer Study Group in Japan [4], which has re-
ported 1-, 3-, 5-, and 10-year survival rates of 85, 64, 45,
and 21 %, respectively, in 6785 cirrhotic patients treated
by hepatic resection between 1988 and 1999. In approxi-
mately 2/3 of patients with tumor recurrence after 2 years,
known as early recurrence, intrahepatic micrometastasis
occurs and is associated with the risk factors tumor size,
Table 1 Clinical and pathological characteristics of the adjuvant






Age 53.8 ± 10.50 56.4 ± 11.7 0.21
Gender (male/female) 45/10 49/13 0.71
AFP level (ng/ml) 289.3 ± 406.1 171.8 ± 335.4 0.09
Child-Pugh class 5.21 ± 0.46 5.37 ± 0.73 0.18
A 54 59 0.37
B 1 3
Hepatitis B virus DNA
value (103 copies/ml)
294.9 ± 601.1 262.3 ± 1011.9 0.83
Surgical resection 0.99
Hemihepatectomy 10 11
Segment resection 31 35







36.4 ± 3.9 36.2 ± 4.1 0.85
Complications 14 (55) 21 (62) 0.321
Average length of stay (days) 12.5 ± 5.7 14.3 ± 5.4 0.08
Liver cirrhosis 47 (55) 53 (62) 0.99
Maximum tumor diameter (cm) 4.9 ± 3.5 5.0 ± 3.1 0.96
>5 cm 17 24 0.34
≤5 cm 38 38
Tumor encapsulation 36 (55) 38 (62) 0.64
Presence of satellite nodules 17 (55) 20 (62) 0.88
Microvascular invasion 24 (55) 26 (62) 0.85
Preemptive lamivudine therapy 18 (55) 22 (62) 0.75
Table 2 Univariate analysis




Hepatitis B virus DNA value 0.000
AFP level 0.000
Child-Pugh class 0.000
1-week-after albumin levels 0.523
Complications 0.085





Presence of satellite nodules 0.000
Differentiation grade 0.124
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microvascular invasion, and satellite nodules. Tsai et al. [5]
reported that 59 % of HCCs were accompanied by micro-
scopic venous invasion; 40.5 % of patients with tumor
diameter ≤2 cm had microscopic venous invasion. Identi-
fying preoperative and intraoperative intrahepatic micro-
metastasis is difficult. The remaining recurrences occur
after 2 years (delayed recurrences) and may correspond to
“de novo” tumors in the oncogenic cirrhotic liver. The risk
factors associated with delayed recurrence are presence of
cirrhosis, hepatitis activity, vascular invasion, moderate or
poorly differentiated HCC, and multinodularity [6]. Our
univariate analysis showed that age, preoperative Child-
Pugh score, preoperative AFP value, preoperative hepatitis
B virus DNA, tumor size, microvascular invasion, and sat-
ellite nodules were associated with postoperative recur-
rence. According to the multivariate regression analysis,
the independent risk factors for postoperative tumor
recurrence were tumor size, microvascular infiltration,
and satellite nodules (P = 0.001, 0.002, and 0.001, respect-
ively). This result is consistent with results reported in the
literature. Thus, intrahepatic micrometastasis and chronic
hepatitis B treatment have become major issues in the
prevention of HCC recurrence.
TACE is currently recognized as the preferred method
of non-surgical treatment for HCC. However, there is a
large controversy about the clinical efficacy of postoper-
ative adjuvant TACE to prevent postoperative recurrence
of HCC. Some scholars believe that adjuvant TACE can
effectively inactivate or inhibit postoperative intrahepatic
residual tumors or the proliferation of tumor tissue, re-
duce the postoperative recurrence rate, and prolong the
survival time of patients. Tanaka K, et al. [7] analyzed
the clinical data of 65 HCC patients who underwent
hepatectomy with adjuvant TACE and showed that it
can effectively reduce the 1-year postoperative recur-
rence rate. Jia ZZ, et al. [8] proved that adjuvant TACE
can reduce the 1-year recurrence rate but could not
reduce the long-term recurrence rate. Adjuvant TACE
performed 1–2 months after surgery is recommended as
a routine method to prevent recurrence. In contrast,
other studies were not in agreement with such conclu-
sions. They reported that adjuvant TACE could decrease
both disease-free survival and overall survival rates. It
was believed that TACE could damage hepatic and im-
munological function and therefore has a negative effect.
In addition, some scholars believe that postoperative ad-
juvant TACE cannot kill all of the tumor cells and that it
is accompanied by tumor necrosis, which can decrease
tumor cell adhesion ability, leading to an increase in
extensive transfer opportunities. Edward CS, et al. [9] re-
ported that in 66 HCC patients who underwent hepatec-
tomy, the 1-, 2-, and 3-year tumor-free survival rates in
the adjuvant TACE group were lower than in the control
group, and the extrahepatic recurrence probability was
higher than in the control group. We found that overall,
adjuvant TACE can improve the tumor-free survival rate
at 1 year, showing a preventive effect on early tumor
recurrence, and that there was an increasing trend for 2-
Table 3 Cox regression analysis
Clinical indicators Regression coefficient Standard error X2 Degrees of freedom P value RR 95 % CI
Tumor size 0.285 0.049 33.993 1 0.000 1.330 1.208–1.464
Age 0.010 0.011 0.016 1 0.900 1.000 0.979–1.424
Microvascular invasion 0.965 0.312 9.587 1 0.002 2.626 1.425–4.838
Presence of satellite nodules 0.942 0.252 14.033 1 0.000 2.566 1.567–4.202
AFP level 0.000 0.000 1.536 1 0.215 1.000 1.000–1.001
Hepatitis B virus DNA value 0.000 0.000 2.473 1 0.116 1.000 1.000–1.000
Child-Pugh class 0.085 0.224 0.146 1 0.702 1.089 0.703–1.688
Table 4 Tumor-free survival rates
Clinical indicators Group A Group B
1 year 2 years 3 years 1 year 2 years 3 years
Overall 45.5 % 36.4 % 30.9 % 64.5 % 50.0 % 41.9 %
Tumor diameter > 5 cm 11.8 % 0 % 0 % 41.7 % 25.0 % 12.5 %
Tumor diameter≤ 5 cm 60.5 % 52.6 % 44.7 % 78.9 % 65.8 % 57.9 %
With microvascular infiltration 12.5 % 4.2 % 0 % 42.3 % 26.9 % 15.4 %
Without microvascular infiltration 77.4 % 67.7 % 61.3 % 77.8 % 63.9 % 55.6 %
With satellite nodules 17.6 % 0 % 0 % 50.0 % 50.0 % 40.0 %
Without satellite nodules 63.2 % 57.9 % 50.0 % 69.0 % 47.6 % 38.1 %
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and 3-year tumor-free survival rates in the adjuvant
TACE group. Postoperative adjuvant TACE may improve
the 2- and 3-year tumor-free survival rates of HCC
patients.
Therefore, establishing the indications of adjuvant
TACE has important clinical significance. However, there
is still a lack of uniform consensus for adjuvant TACE.
Many retrospective studies focused on the risk factors of
HCC recurrence, such as microvascular invasion, satellite
nodules, and tumor size, but their conclusions were not
the same. Xi T et al. [10] reported that in 823 HCC pa-
tients who underwent hepatectomy, adjuvant TACE can-
not effectively reduce the recurrence rate in patients with
a tumor diameter less than 3 cm. TACE can improve
tumor-free survival rates in patients with a tumor diam-
eter of 3–10 cm, positive AFP value and vascular invasion
or patients with a tumor diameter greater than 10 cm,
AFP positivity, and multiple satellite nodules associated
with vascular invasion. Li Ke-Wei et al. [11] reported
that in 76 HCC patients who underwent hepatectomy,
postoperative adjuvant TACE may improve 1-, 3-, and
5-year tumor-free and overall survival rates of HCC
patients with microscopic venous invasion, but no
statistical significance was found. TACE can be used as a
preventative treatment but not a routine procedure for
such patients. Peng BG et al. [12] reported that in 126
cases of HCC patients with portal vein tumor thrombus
who underwent hepatectomy, the adjuvant TACE group
had a better tumor-free survival rate relative to the control
group. Multivariate regression analysis showed that tumor
size, microvascular infiltration, and satellite nodules were
three independent risk factors affecting tumor recurrence.
We found that in patients with tumor diameter >5 cm,
sequential TACE could effectively improve the 1-year and
2-year postoperative tumor-free survival rates (P = 0.04
and 0.03, respectively). Postoperative adjuvant TACE may
improve the 3-year tumor-free survival rate, but the differ-
ence was not statistically significant (P > 0.05). For HCC
patients with tumor size ≤5 cm, postoperative adjuvant
TACE may improve 1-, 2-, and 3-year tumor-free survival
rates, but no statistical significance was found. For
patients with microvascular infiltration or satellite nod-
ules, postoperative adjuvant TACE can improve the 1-, 2-,
and 3-year tumor-free survival rates. For patients without
microvascular infiltration or without satellite nodules,
postoperative adjuvant TACE cannot improve 1-, 2-, or 3-
year tumor-free survival rates. For patients with tumor
size >5 cm, with microvascular infiltration or with satellite
nodules, postoperative adjuvant TACE was suggested.
Regarding the timing and method for adjuvant TACE,
there is no uniform opinion. Most HCC recurrent tumors
appeared 2 years after surgery, so most scholars believe
that adjuvant TACE after surgery should be carried out as
soon as possible. The recommended schedule is 1 month
postoperative. Pengfei Liu et al. [8] proposed that adjuvant
TACE should be carried out within 1–2 months after sur-
gery as a regular method of prevention. However, there is
controversy regarding the number of times postoperative
adjuvant TACE should be administered. Some scholars
believe that if patients with liver function can tolerate it,
adjuvant TACE treatment should be repeated throughout
the entire recurrence peak period (1–2 years after sur-
gery). However, other scholars believe that repeated adju-
vant TACE treatment in a cirrhosis background may lead
to an increase in hepatic dysfunction. Therefore, unless
the liver is non-cirrhotic, adjuvant TACE should not be
repeatedly implemented. Xi T et al. showed that single
TACE is superior to repeated TACE [10].
In malignant tumors associated with chronic hepatitis B,
especially lymphoma, systemic chemotherapy has been
confirmed to cause hepatitis B virus reactivation in a large
number of patients. In China, nearly 90 % of patients with
HCC are associated with chronic hepatitis B. Increasing at-
tention has been directed toward whether TACE can cause
hepatitis B virus reactivation in HCC patients and the post-
operative liver function and prognosis. There is no agree-
ment by scholars in this field of research. Jeong won Jang
et al. [13] found that transarterial chemo-lipiodolization
can reactivate HBV, and HBeAg-positive HCC patients re-
ceiving chemo-lipiodolization should be closely monitored
for HBV reactivation. Preemptive lamivudine therapy dem-
onstrated excellent efficacy in reducing hepatitis due to
HBV reactivation and hepatic morbidity during TACE.
Preemptive therapy should be considered in HCC patients
with an HBV DNA level higher than 104 copies/mL. Fur-
ther studies are needed to confirm the value of this ap-
proach in patients with low-level viremia [14]. However,
Park JW et al. [15] believed that one session of TACE using
doxorubicin and lipiodol does not significantly aggravate
HBV hepatitis in patients with HBV-related HCC. Lao
XM, et al. [16] believed that HBV DNA changes after
TACE included reactivation and decreased and stable HBV
DNA levels. Although HBV reactivation did not necessarily
result in the exacerbation of liver damage and most HCC
patients with Child-Pugh grade A and B tolerated TACE
Table 5 Tumor-free survival rates
Clinical indicators 1 year 2 years 3 years
X2 P X2 P X2 P
Overall 4.29 0.04 2.20 0.14 1.52 0.22
Tumor diameter > 5 cm 4.29 0.04 4.98 0.03 2.23 0.13
Tumor diameter ≤5 cm 3.06 0.08 1.36 0.24 1.32 0.25
With microvascular infiltration 5.50 0.02 4.81 0.03 4.01 0.045
Without microvascular infiltration 0.001 0.97 1.11 0.74 0.23 0.64
With satellite nodules 4.22 0.04 11.6 0.01 8.68 0.03
Without satellite nodules 0.31 0.58 0.85 0.36 1.15 0.28
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well, careful post-procedure monitoring and management
is needed. Our results showed that hepatitis B virus reacti-
vation can occur in patients undergoing postoperative
adjuvant TACE; thus, antiviral treatment was suggested for
these patients.
Conclusions
Postoperative adjuvant TACE can improve the 1-year
disease-free survival rate of HCC patients. Postoperative
adjuvant TACE may improve 2- and 3-year disease-free
survival rates, but no statistical significance was found. For
patients with tumor size >5 cm, postoperative adjuvant
TACE can improve 1- and 2-year disease-free survival
rates, and postoperative adjuvant TACE may improve the
3-year disease-free survival rate. For HCC patients with
tumor size ≤5 cm, postoperative adjuvant TACE may
improve 1-, 2-, and 3-year disease-free survival rates, but
no statistical significance was found. For patients with
microvascular infiltration or satellite nodules, postoperative
adjuvant TACE can improve 1-, 2-, and 3-year disease-free
survival rates. For patients without microvascular infiltra-
tion or without satellite nodules, postoperative adjuvant
TACE cannot improve 1-, 2-, or 3-year disease-free survival
rates. For patients with tumor size >5 cm, with micro-
vascular infiltration or with satellite nodules, postoperative
adjuvant TACE was suggested. Hepatitis B virus reactiva-
tion can occur in patients with postoperative adjuvant
TACE; thus, antiviral treatment was suggested for these
patients.
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